NEW YORK (GenomeWeb) — Computational drug discovery firm TwoXAR has partnered with Adynxx to identify new therapeutic candidates for endometriosis, the companies said on Thursday.
Under the terms of the deal, Mountain View, California-based TwoXAR will use its proprietary artificial intelligence technology — which leverages a variety of biomedical data including genomic, proteomic, and clinical data — to identify orally delivered, non-hormonal drug candidates for treating or preventing endometriosis and its associated symptoms. San Francisco-based Adynxx will select certain drug candidates for efficacy testing in animal models of endometriosis and will be responsible for any additional preclinical and clinical development.
Additional terms were not disclosed.
"This collaboration with Adynxx expands the scope of our portfolio of disease programs to include specific indications within the therapeutic area of fibrotic diseases," TwoXAR Cofounder and CEO Andrew Radin said in a statement.
In early 2017, TwoXAR partnered with Santen — the US subsidiary of Japanese specialty ophthalmology company Santen Pharmaceuticals — to discover drug candidates for glaucoma. It also has collaborations with the University of Chicago in cardiac disease and Stanford University in dermatology.